that's what I mean the exercise price, I don't know what it is or will be. But anyway I could have been a winner if I were a bondholder. That was always the real deal here especially the senior holders. They have been sleeping well and booking deep forever..
They get a penny ( 5 million for their trouble) and a chance to buy back in. The true owners now will own this stock, senior debt. They have rode this thing all the way into the equity. This company has always been a money machine for them and still is.
No need to panic sell because the panic sell time has past and is now in the price. You have time to ponder what to do at this price. GBIM has two shots on goal in the last half of this year. Look at the low market cap for this stock, it is nothing with such a tight float. If you do not know what to do - I say sell half and keep half. This is what I do when a trade goes bad. GILD is eager to build a drug pipeline, nothing to take this company out if only we can show them something.
gbim with it's slim pipeline is looking for the next Pharmasset. They were lucky and it was one hell of a buy. They really do need to start buying and building out the pipe. Sure hope they can find something they can use in GBIM.
yep, really seems this company is just in the business of granting themselves free options. Shareholders get to watch directors get more and more free shares to sell to more shareholders. Good job if you can find it. They did.
Yep, hope it doesn't get that far. Also keep in mind GBIM has 250 mil in tax write offs. That should be worth something.
I like your outlook and can this stock get any cheaper. Just hold and see what happens. Anything that happens positively would explode the share price when something priced as nothing becomes something again. Potential/valuation is huge gap.
You have one part time CEO, one scientist, one accountant and your drug keeps drilling dry wells. If this turns out to be the final answer at the end of the year, what do you have? Other side, something actually happens or Partners see something useful in the drug. Questions, why did insiders stop selling, why still engaged to sell company, why is GILD still interested, still have CELG's report in the works.
what is the exercise price for these. Looks like they are giving away 10 percent of the company. Nice for the directors.
I really hope you are right wbar. I was looking at it this way: Drug was a flop at 24 weeks in. So why doesn't GILD pull the plug on this? It didn't work in the chronic end and so far not in the 24 week naive study either, but it did work in healthy individuals. GILD must see something or just throwing good money after bad. No real press release about the 24 week failure just a roll over report to 48 weeks and last half of the year. I sure hope the value of 4774 is more than zero.
� a Phase 2 clinical trial initiated in 2013, GS-US-330-0101, or the 0101 trial, investigating GS-4774 in combination with ongoing oral antiviral treatment in patients with chronic HBV infection. The 0101 trial was a multicenter, multinational trial that enrolled 178 patients in a randomized, open-label design comparing three different doses of GS-4774 (2YU, 10YU or 40YU), administered in combination with oral antiviral therapy versus antiviral treatment alone. The primary endpoint for this trial was decline in serum HBV surface antigen, or HBsAg. In May 2015, we announced top line results from this study. Patients treated with the highest dose of GS-4774 plus ongoing oral antiviral therapy, or OAV, did not show a reduction in HBsAg at week 24, the primary endpoint of the study. These study results were presented at The Liver Meeting, November 13-17, 2015 in San Francisco, CA.
� a second Phase 2 clinical trial initiated in 2014, GS-US-330-1401, or the 1401 trial, investigating GS-4774 in patients with chronic HBV infection who are currently not receiving treatment. The 1401 trial is a multicenter, multinational trial designed to enroll 175 patients in a randomized, open-label design comparing three different doses of GS-4774 (2YU, 10YU, or 40YU), administered in combination with tenofovir disoproxil fumarate, or TDF, versus TDF alone. The 1401 trial is fully enrolled. The 24-week results for this trial did not show a statistical difference between control and treatment arms and the 48-week results are projected to be available in the second half of 2016.
Death by a thousand cuts. Dilute as a means of using pay as go ATM. Longs will get bill in the end on the reverse split.
company going to get refi'd or is this a chapter 11 solution?
Good ole Edstrom, he sold all the way down and still has shares. But Matt has plenty of tools in his toolbox: share dilution, reverse split, BK filing after about six months. They always keep you looking forward and then disappoint.
Absolutely, King. Unfortunately, I drank the kool Aid but got smarter as time went on. I have been on the sidelines for a while too. I think someone gets paid for Afrezza but may not be present shareholders. They Simply cannot get it done, need a management change or bankruptcy to decide the issue of making it happen.
Question is does mankind have the rockets to win the war? If not, afrezza will belong to someone else.
Afrezza's payoff seems to be meant for someone other than the present longs. Payoff seems to slide out the back door.